Exchange Bulletin

BriaCell Therapeutics Corp. (BCT) To Trade On Toronto Stock Exchange

December 29, 2021
Issuer: BriaCell Therapeutics Corp. (the "Company")
Security: Common shares (the "Shares")
Symbol: BCT
Number of securities issued and outstanding: 15,946,642 Shares
Number of securities reserved for issuance: 10,189,831 Shares
Listing category: Industrial, Non-Exempt
Trading currency: CDN$
Listing and posted for trading date: December 31, 2021 (at the opening)
Other market(s): The Shares have been listed on TSX Venture Exchange ("TSXV") in their current form since January 2, 2020 (and since December 3, 2014 on a pre-consolidated basis) under the symbol "BCT". The Shares will be delisted from TSXV on December 31, 2021, upon commencement of trading on Toronto Stock Exchange ("TSX"). The Shares have also been listed on the NASDAQ Capital Market since February 24, 2021.
Temporary market maker: Canaccord Genuity Corp.
Security ownership registration: Certificated Issue
Investor relations: Dr. William V. Williams
President and Chief Executive Officer
Jules Abraham
Director of Public Relations, Core IR
Incorporation: Business Corporations Act (British Columbia)
Fiscal year end: July 31
Nature of business: The Company is an immuno-oncology biotechnology company with a strong focus on cancer immunotherapy
Transfer agent and registrar: Computershare Investor Services Inc. at its principal office in Vancouver
Normal course issuer bid: Through the facilities of TSX (or TSXV, as applicable) and the NASDAQ Capital Market up to 1,341,515 Shares during the period commencing September 28, 2021 to September 27, 2022 representing approximately 10% of the Company's public float. (There have been 501,703 Shares purchased to date on TSXV.)
Dividends: None anticipated in the foreseeable future
Sponsorship: Not applicable
TSX contact: Chris Birkett,
Managing Director,
Toronto Stock Exchange